A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
ConclusionPatients with active nonradiographic axial SpA treated with golimumab had significantly greater improvement in symptoms compared with patients treated with placebo. Golimumab was well tolerated and had a favorable risk/benefit profile.
Source: Arthritis and Rheumatism - Category: Rheumatology Authors: J. Sieper, D. van der Heijde, M. Dougados, W. P. Maksymowych, B. B. Scott, J. A. Boice, Y. Berd, G. Bergman, S. Curtis, A. Tzontcheva, S. Huyck, H. H. Weng Tags: Spondyloarthritis Source Type: research
More News: Ankylosing Spondylitis | Arthritis | Back Pain | Chronic Pain | Eyes | MRI Scan | Pain | Rheumatology | Study